Received Oct 31, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | K4JH7 | — |
administered a pediatric dose of Engerix-B to an adult; administered a pediatric dose of Engerix-B to an adult; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult use of a child product in a 64-year-old female patient who received HBV (Engerix B Junior) (batch number K4JH7, expiry date 09-JUL-2026) for prophylaxis. On 13-OCT-2025, the patient received Engerix B Junior. On 13-OCT-2025, an unknown time after receiving Engerix B Junior, the patient experienced adult use of a child product (Verbatim: administered a pediatric dose of Engerix-B to an adult) and underdose (Verbatim: administered a pediatric dose of Engerix-B to an adult). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 13-OCT-2025 Medical assistant reported she administered a pediatric dose of Engerix-B to an adult today (date of reporting).